Categories: Public Companies

Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will speak at the Forbes Global CEO Conference being held on October 15-16, 2019, in Singapore.

In the panel titled “Health and Wellness: The Long Haul,” taking place on Tuesday, October 15, at 3:15 p.m. local time, Dr. Du will address the complex facets of healthcare and discuss opportunities that exist to improve patient care, adopt new technologies and encourage healthier lifestyles.

Now in its 19th year, the prestigious Conference is an annual gathering for more than 400 global CEOs, entrepreneurs, investors and thought leaders to discuss and debate key issues of global concern and to build new partnerships.

Under the theme “Transcending the Turbulence,” this year’s Conference will examine how CEOs, companies and countries are navigating the challenges and opportunities arising from the current state of the global economy.

About Zai Lab

Zai Lab (ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

Contact:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Lee Roth
Burns McClellan, on behalf of Zai Lab
212-213-0006
lroth@burnsmc.com

IR Press

Share
Published by
IR Press

Recent Posts

Treasury Issues Final Rule Expanding CFIUS Coverage of Real Estate Transactions Around More Than 60 Military Installations

WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…

5 days ago

U.S. Department of the Treasury’s CDFI Fund and Federal Housing Finance Agency Collaborate to Bolster CDFI Access to Capital

WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…

5 days ago

Report on U.S. Portfolio Holdings of Foreign Securities at Year-End 2023

Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…

6 days ago

READOUT: U.S. Department of the Treasury Hosts Roundtable Discussion on the Financial Sector’s Response to Recent Hurricanes

WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…

6 days ago

READOUT: Sixth Meeting of the Financial Working Group Between the United States and the People’s Republic of China

WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…

6 days ago

Treasury Sanctions Key Members of La Linea, a Group Involved in Trafficking Fentanyl into the United States

WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…

6 days ago